Logo image of ALVIO.PA

VALERIO TX (ALVIO.PA) Stock Fundamental Analysis

EPA:ALVIO - Euronext Paris - Matif - FR0010095596 - Common Stock - Currency: EUR

0.0635  +0 (+1.93%)

Fundamental Rating

1

Overall ALVIO gets a fundamental rating of 1 out of 10. We evaluated ALVIO against 71 industry peers in the Biotechnology industry. ALVIO may be in some trouble as it scores bad on both profitability and health. ALVIO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ALVIO had negative earnings in the past year.
ALVIO had a negative operating cash flow in the past year.
In the past 5 years ALVIO reported 4 times negative net income.
ALVIO had a negative operating cash flow in each of the past 5 years.
ALVIO.PA Yearly Net Income VS EBIT VS OCF VS FCFALVIO.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -20M -40M -60M

1.2 Ratios

ALVIO has a Return On Assets of -67.00%. This is in the lower half of the industry: ALVIO underperforms 67.61% of its industry peers.
The Return On Equity of ALVIO (-488.76%) is worse than 69.01% of its industry peers.
Industry RankSector Rank
ROA -67%
ROE -488.76%
ROIC N/A
ROA(3y)-38.08%
ROA(5y)-40.32%
ROE(3y)-81.06%
ROE(5y)-87.11%
ROIC(3y)N/A
ROIC(5y)N/A
ALVIO.PA Yearly ROA, ROE, ROICALVIO.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50 -100 -150

1.3 Margins

ALVIO's Gross Margin of 74.75% is fine compared to the rest of the industry. ALVIO outperforms 73.24% of its industry peers.
ALVIO's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for ALVIO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 74.75%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.31%
GM growth 5Y-6.1%
ALVIO.PA Yearly Profit, Operating, Gross MarginsALVIO.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K

More info and screens

0

2. Health

2.1 Basic Checks

ALVIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ALVIO has more shares outstanding
Compared to 5 years ago, ALVIO has more shares outstanding
Compared to 1 year ago, ALVIO has a worse debt to assets ratio.
ALVIO.PA Yearly Shares OutstandingALVIO.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M
ALVIO.PA Yearly Total Debt VS Total AssetsALVIO.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -4.02, we must say that ALVIO is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of ALVIO (-4.02) is worse than 61.97% of its industry peers.
A Debt/Equity ratio of 2.88 is on the high side and indicates that ALVIO has dependencies on debt financing.
The Debt to Equity ratio of ALVIO (2.88) is worse than 66.20% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.88
Debt/FCF N/A
Altman-Z -4.02
ROIC/WACCN/A
WACC7.24%
ALVIO.PA Yearly LT Debt VS Equity VS FCFALVIO.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M 60M 80M 100M

2.3 Liquidity

A Current Ratio of 0.90 indicates that ALVIO may have some problems paying its short term obligations.
ALVIO has a Current ratio of 0.90. This is in the lower half of the industry: ALVIO underperforms 71.83% of its industry peers.
ALVIO has a Quick Ratio of 0.90. This is a bad value and indicates that ALVIO is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.90, ALVIO is doing worse than 69.01% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.9
Quick Ratio 0.9
ALVIO.PA Yearly Current Assets VS Current LiabilitesALVIO.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 31.63% over the past year.
ALVIO shows a strong growth in Revenue. In the last year, the Revenue has grown by 31.18%.
The Revenue for ALVIO have been decreasing by -21.74% on average. This is quite bad
EPS 1Y (TTM)31.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)31.18%
Revenue growth 3Y0.37%
Revenue growth 5Y-21.74%
Sales Q2Q%N/A

3.2 Future

ALVIO is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -33.68% yearly.
The Revenue is expected to decrease by -29.53% on average over the next years. This is quite bad
EPS Next Y-136.11%
EPS Next 2Y-50.92%
EPS Next 3Y-33.68%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-29.53%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ALVIO.PA Yearly Revenue VS EstimatesALVIO.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2026 20M 40M 60M
ALVIO.PA Yearly EPS VS EstimatesALVIO.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 0.2 -0.2 0.4 -0.4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALVIO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALVIO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALVIO.PA Price Earnings VS Forward Price EarningsALVIO.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALVIO.PA Per share dataALVIO.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.05 -0.1

4.3 Compensation for Growth

A cheap valuation may be justified as ALVIO's earnings are expected to decrease with -33.68% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-50.92%
EPS Next 3Y-33.68%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALVIO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VALERIO TX

EPA:ALVIO (5/9/2025, 7:00:00 PM)

0.0635

+0 (+1.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)09-25 2024-09-25
Earnings (Next)N/A N/A
Inst Owners28.6%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap9.80M
Analysts34.29
Price Target0.01 (-84.25%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-90%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)7.14%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.19
P/FCF N/A
P/OCF N/A
P/B 2.44
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.12
EYN/A
EPS(NY)-0.1
Fwd EYN/A
FCF(TTM)-0.11
FCFYN/A
OCF(TTM)-0.11
OCFYN/A
SpS0.01
BVpS0.03
TBVpS-0.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -67%
ROE -488.76%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 74.75%
FCFM N/A
ROA(3y)-38.08%
ROA(5y)-40.32%
ROE(3y)-81.06%
ROE(5y)-87.11%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.31%
GM growth 5Y-6.1%
F-Score3
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 2.88
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 6.67%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.9
Quick Ratio 0.9
Altman-Z -4.02
F-Score3
WACC7.24%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)15.88%
Cap/Sales(5y)11.02%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next Y-136.11%
EPS Next 2Y-50.92%
EPS Next 3Y-33.68%
EPS Next 5YN/A
Revenue 1Y (TTM)31.18%
Revenue growth 3Y0.37%
Revenue growth 5Y-21.74%
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-29.53%
Revenue Next 5YN/A
EBIT growth 1Y5.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-147.5%
EBIT Next 3Y-37.95%
EBIT Next 5YN/A
FCF growth 1Y-137.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-142.35%
OCF growth 3YN/A
OCF growth 5YN/A